What are Lupin CEO Vinita Gupta’s plans for growth in US & China?
In conversation with Business Standard’s Sohini Das, Lupin CEO Vinita Gupta shared her company’s growth plans in the US and in China. Let us listen in to the interview
Topics
Lupin | Pharma | US China
Sohini Das |
Last Updated at February 9, 2022 08:30 IST
Q1: What are the growth expectations from key brands, like Solosec and albuterol? How’re the pricing pressure and cost pressure affecting your plans in the US market? Ans: >Respiratory products, like albuterol, have become a growth driver for Lupin in the US >Generic version of Brovana, another respiratory product, have about 45% share in the category >Rest of the businesses in the US has been stable Q2: What are the major product launches lined up for the US? Ans: >Expect to launch a couple of products in the US, like Spiriva, in the second half of this calendar year or the first quarter of FY23 >Expect to launch pegfilgrastim, Lupin’s first biosimilar in the US, in second half of FY23 >Hope to get the product approved following inspection of its Pune site Q3: Are you planning to shift more production to India to offset growing cost pressures in the US? Ans: >Production of nasal spray products, developed in Somerset, US, moved to India >Production of other first to file (FTF) products in the US, are being transferred to contract manufacturers in the US and India >Exploring ways to improve cost position in products and risk mitigation Q4: The India business is flat sequentially in Q3FY22.
What is the outlook?
Ans: >India business has grown 12% y-o-y, but sequentially it’s flat >That’s because last year Lupin saw major growth in the respiratory products portfolio >Launched Molnupiravir in the Covid products portfolio >In India, more contribution will come from the diagnostic business Q5: How are your China entry plans shaping up? Ans: >Announced partnership with Fancoo for CNS (Central Nervous System) products >The products are awaiting approval, followed by the launch in China >Working on respiratory products (developed for the US) for China, and simultaneously working out the entry strategy
Watch video
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
First Published: Wed, February 09 2022. 08:30 IST
